Literature DB >> 16525203

Common bile duct injection as a novel method for establishing red fluorescent protein (RFP)-expressing human pancreatic cancer in nude mice.

Kazuhiko Tsuji1, Meng Yang, Ping Jiang, Anirban Maitra, Sharmeela Kaushal, Kensuke Yamauchi, Matthew H Katz, Abdool R Moossa, Robert M Hoffman, Michael Bouvet.   

Abstract

CONTEXT: In our previous pancreatic cancer mouse models, we have used surgical orthotopic implantation of human pancreatic tumors to establish clinically relevant fluorescent mouse models of pancreatic cancer.
OBJECTIVE: Since exocrine pancreatic cancer is thought to arise from the cells lining the ducts of the pancreas, we hypothesized that direct injection of tumor cells into the common bile duct would also result in pancreatic tumor formation and metastasis. INTERVENTION: In this study we injected a suspension of the low passage human pancreatic cancer cell line xPA-1 transfected with red fluorescent protein into the common bile duct of nude mice. MAIN OUTCOME MEASURE: Pancreatic tumor growth and metastasis formation was monitored by intravital and whole body fluorescent imaging. Single fluorescent pancreatic cancer cells were imaged in the pancreatic duct shortly after injection using the Olympus OV100 Whole Mouse Imaging System.
RESULTS: Five days after tumor cell injection in the common bile duct, tumor colonies could be imaged forming within the pancreatic duct. Metastases in the liver were imaged 14 days post common bile duct injection. By day 28, massive tumors were imaged encompassing the entire pancreas. By day 42, RFP-expressing metastases were imaged in the omentum and liver.
CONCLUSION: Common bile duct injection is a novel technique for the development of fluorescent mouse models of metastatic pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16525203

Source DB:  PubMed          Journal:  JOP        ISSN: 1590-8577


  6 in total

1.  Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF.

Authors:  Eric A Murphy; David J Shields; Konstantin Stoletov; Elena Dneprovskaia; Michele McElroy; Joshua I Greenberg; Jeff Lindquist; Lisette M Acevedo; Sudarshan Anand; Bharat Kumar Majeti; Igor Tsigelny; Adrian Saldanha; Breda Walsh; Robert M Hoffman; Michael Bouvet; Richard L Klemke; Peter K Vogt; Lee Arnold; Wolfgang Wrasidlo; David A Cheresh
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-12       Impact factor: 11.205

2.  Cancer-cell-secreted extracellular vesicles suppress insulin secretion through miR-122 to impair systemic glucose homeostasis and contribute to tumour growth.

Authors:  Minghui Cao; Roi Isaac; Wei Yan; Xianhui Ruan; Li Jiang; Yuhao Wan; Jessica Wang; Emily Wang; Christine Caron; Steven Neben; Denis Drygin; Donald P Pizzo; Xiwei Wu; Xuxiang Liu; Andrew R Chin; Miranda Y Fong; Ziting Gao; Kaizhu Guo; Oluwole Fadare; Richard B Schwab; Yuan Yuan; Susan E Yost; Joanne Mortimer; Wenwan Zhong; Wei Ying; Jack D Bui; Dorothy D Sears; Jerrold M Olefsky; Shizhen Emily Wang
Journal:  Nat Cell Biol       Date:  2022-05-30       Impact factor: 28.213

3.  Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer.

Authors:  Clinton Yam; Ming Zhao; Katsuhiro Hayashi; Huaiyu Ma; Hiroyuki Kishimoto; Michele McElroy; Michael Bouvet; Robert M Hoffman
Journal:  J Surg Res       Date:  2009-03-31       Impact factor: 2.192

4.  High resolution 3D MRI of mouse mammary glands with intra-ductal injection of contrast media.

Authors:  Erica Markiewicz; Xiaobing Fan; Devkumar Mustafi; Marta Zamora; Brian B Roman; Sanaz A Jansen; Kay Macleod; Suzanne D Conzen; Gregory S Karczmar
Journal:  Magn Reson Imaging       Date:  2014-08-29       Impact factor: 2.546

5.  Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers.

Authors:  Jocelyn Logan-Collins; Ryan M Thomas; Peter Yu; Dawn Jaquish; Evangeline Mose; Randall French; William Stuart; Rebecca McClaine; Bruce Aronow; Robert M Hoffman; Susan E Waltz; Andrew M Lowy
Journal:  Cancer Res       Date:  2010-01-26       Impact factor: 12.701

6.  The tumor-educated-macrophage increase of malignancy of human pancreatic cancer is prevented by zoledronic acid.

Authors:  Yukihiko Hiroshima; Ali Maawy; Mohamed K Hassanein; Rhiana Menen; Masashi Momiyama; Takashi Murakami; Shinji Miwa; Mako Yamamoto; Fuminari Uehara; Shuya Yano; Ryutaro Mori; Ryusei Matsuyama; Takashi Chishima; Kuniya Tanaka; Yasushi Ichikawa; Michael Bouvet; Itaru Endo; Robert M Hoffman
Journal:  PLoS One       Date:  2014-08-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.